NCT05867615View on ClinicalTrials.gov

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2028

Conditions
Cancer
Interventions
DRUG

[177Lu]Lu-PSMA I&T

177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.

Trial Locations (2)

47014

UO Medicina Nucleare, IRCCS IRST, Meldola

47521

UO Medicina Nucleare, AUSL della Romagna, Cesena

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER